Pfizer has finalized a $5.3 billion U.S. government agreement to supply its oral antiviral treatment, extending distribution through hospital systems and retail pharmacy networks.
The deal reflects continued procurement of outpatient therapies as health agencies maintain stockpiles for seasonal demand.
Wholesalers and group purchasing organizations are updating allocation forecasts for the second half of the year.
